About Spindlin interactor and repressor of chromatin-binding protein
Spindlin interactor and repressor of chromatin-binding protein (SPINDOC) is a protein
from Homo sapiens identified by UniProt accession
Q9BUA3, 381 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Spindlin interactor and repressor of chromatin-binding protein |
| UniProt accession | Q9BUA3 |
| Gene | SPINDOC |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- body height · score 0.28
- age at menarche · score 0.17
- low density lipoprotein cholesterol measurement · score 0.06
- hepatocellular carcinoma · score 0.05
- mean corpuscular hemoglobin · score 0.02
- cancer · score 0.02
- neoplasm · score 0.02
- insulin resistance · score 0.01
- pheochromocytoma-paraganglioma · score 0.00
- metastatic melanoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BUA3-F1 | alphafold | PREDICTED | 51.66 | — |
Amino-acid sequence (381 residues)
MALKAEGAAL DCFEVTLKCE EGEDEEEAMV VAVIPRPEPM LRVTQQEKTP PPRPSPLEAG SDGCEEPKQQ VSWEQEFLVG SSPGGSGRAL CMVCGAEIRA PSADTARSHI LEQHPHTLDL SPSEKSNILE AWSEGVALLQ DVRAEQPSPP NSDSGQDAHP DPDANPDAAR MPAEIVVLLD SEDNPSLPKR SRPRGLRPLE LPAVPATEPG NKKPRGQRWK EPPGEEPVRK KRGRPMTKNL DPDPEPPSPD SPTETFAAPA EVRHFTDGSF PAGFVLQLFS HTQLRGPDSK DSPKDREVAE GGLPRAESPS PAPPPGLRGT LDLQVIRVRM EEPPAVSLLQ DWSRHPQGTK RVGAGDTSDW PTVLSESSTT VAGKPEKGNG V
Explore Spindlin interactor and repressor of chromatin-binding protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets